Conference Update | Omnihealth Practice | Page 4

Conference Update

View

Bookmark

Oncology
2 years ago, OP Editor

Better survival after breast conservation than mastectomy for older patients with early stage disease, says a Dutch study

The largest ever conducted population-based study, involving almost 130,000 patients in the Netherlands, found that breast-conserving surgery plus rad...
Bookmark

Cardiology
2 years ago, OP Editor

NORSTENT: Bare-Metal Stents No Worse Than Drug-Eluting Stents in Mortality

The largest randomized coronary stent trial in history, with >9,000 CAD patients underwent PCI enrolled, has found no difference between contempora...
Bookmark

Cardiology
2 years ago, OP Editor

NACIAM shows N-Acetylcysteine reduces infarct size in STEMI

The addition of N-acetylcysteine (NAC) to glyceryl trinitrate (GTN) appears to significantly reduce the infarct size by nearly one-third and increase ...
Bookmark

Diabetes
2 years ago, OP Editor

Sustain-6: Semaglutide shows non-inferiority of cardiovascular outcomes to standard care in type 2 diabetes

Semaglutide, a glucagon-like peptide (GLP)-1 agonist developed by Novo Nordisk, has demonstrated non-inferiority in cardiovascular (CV) risk, in fact,...
Bookmark

Oncology
2 years ago, OP Editor

Active monitoring, surgery or radiotherapy: what is the optimal choice in localized prostate cancer?

The unprecedented, 10-year, head-to-head trial to compare the effectiveness of active monitoring, surgery and radiotherapy in localized prostate cance...
Bookmark

Oncology
2 years ago, OP Editor

1st 10-year clinical experience of aromatase inhibitor in breast cancer

In hormone receptor (HR)-positive, early breast cancer, the use of aromatase inhibitor (AI) is limited to five years only owing to the lack of efficac...
Bookmark

Oncology
2 years ago, OP Editor

Pembrolizomab—setting a new standard for lung cancer first-line therapy

Immunotherapy with anti-PD-1 antibodies, Pembrolizumab (Keytruda, Merck & Co), was found to be superior to platinum-based doublet chemotherapy, th...
Bookmark

Hematology
3 years ago, OP Editor

Daratumumab combo– setting a new standard for refractory multiple myeloma?

In just a week of time, a CD38 monoclonal antibody–daratumumab (Darzalex, Janssen)- has been reported twice to markedly reduce disease progression b...
Bookmark

Oncology
3 years ago, OP Editor

Right vs Left: Big difference in colorectal cancer

The detailed findings of the study was presented on 5-June in 2016, by the lead investigator Alan P Venook, MD, professor of medicine at the Universit...
Bookmark

Diabetes
3 years ago, OP Editor

EMPA-REG: Empagliflozin delays renal disease progression in T2D

EMPA-REG OUTCOME trial was the first positive FDA-mandated cardiovascular (CV) outcome study for anti-hyperglycemia medicine reported last fall.1 Yet,...

Copyright © 2019 by Omnihealth Practice. All Rights Reserved.